Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma - PubMed (original) (raw)
Clinical Trial
. 2008 Dec;16(12):2022-9.
doi: 10.1038/mt.2008.196. Epub 2008 Sep 16.
Jianda Yuan, Sarah Powel, Humilidad F Gallardo, Teresa S Rasalan, Christina Gonzalez, Gregor Manukian, Jian Wang, Yan Zhang, Paul B Chapman, Susan E Krown, Philip O Livingston, Samuel Ejadi, Katherine S Panageas, Manuel E Engelhorn, Stephanie L Terzulli, Alan N Houghton, Jedd D Wolchok
Affiliations
- PMID: 18797450
- PMCID: PMC3909666
- DOI: 10.1038/mt.2008.196
Clinical Trial
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
Miguel-Angel Perales et al. Mol Ther. 2008 Dec.
Abstract
Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances immune responses by inducing proliferation, maturation, and migration of dendritic cells (DCs) as well as expansion and differentiation of B and T lymphocytes. The potency of DNA vaccines can be enhanced by the addition of DNA encoding cytokines, acting as molecular adjuvants. We conducted a phase I/II trial of human GM-CSF DNA in conjunction with a multipeptide vaccine (gp100 and tyrosinase) in stage III/IV melanoma patients. Nineteen human leukocyte antigen (HLA)-A*0201+ patients were treated. Three dose levels were studied: 100, 400, and 800 microg DNA/injection, administered subcutaneously every month with 500 microg of each peptide. In the dose-ranging study, three patients were treated at each dose level. The remaining patients were then treated at the highest dose. Most toxicities were grade 1 injection-site reactions. Eight patients (42%) developed CD8+ T-cell responses, defined by a > or =3 SD increase in baseline reactivity to tyrosinase or gp100 peptide in tetramer or intracellular cytokine staining (ICS) assays. There was no relationship between dose and T-cell response. Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant.
Figures
Figure 1. Immunization with GM-CSF DNA followed by tyrosinase and gp100 peptides induced peptide-specific CD8+ T cells assessed by tetramer binding and IFNγ production
PBMCs were collected pre-vaccination, and at several time points during or after vaccination (C = week 7, D = week 11, and E = week 17) and analyzed by tetramer and ICS IFNγ assays. (a) Two patients with positive tetramer assays – patient # 4, Tyrosinase time points D and E; patient # 20 gp100 time point D, and (b) the corresponding ICS IFNγ assays are shown. Only patient # 20 – time points C and D – are positive. Pre-vac, pre-vaccination.
Figure 2. GP100 tetramer-reactive CD8+ cells in the responder population have an effector memory phenotype
PBMCs were analyzed by tetramer assay after in vitro culture using gp100209-217 ITDQVPFSV peptide. (a) Dot plots from patient # 20 at time point D are shown. (b) Contour plots from patient # 20 at time point D show CD3+CD8+ T cells analyzed for tetramer reactivity. Upper plots gated CD3+CD8+tetramer+ T cells; lower row plots gated on CD3+CD8+tetramer-T cells.
Figure 3. Phenotypic characterization of cells secreting IFNγ in ICS assays
ICS assays were performed with CD45RO, CD62L, CD127, CD107a, and granzyme B. (a) Representative dot plots from patient # 20 at time point D are shown. (b) Contour plots from patient # 20 at time point D show the gated CD3+CD8+IFN-γ+ T cells. Upper plots gated on CD3+CD8+IFNγ+ T cells; lower row plots gated on CD3+CD8+IFNγ- T cells.
Figure 4. Polyfunctional antigen specific CD8+ T cells are induced following immunization
(a) Representative dot-plots from sample patient #12 at time point C. Single function gates were set based on negative control (unstimulated sample, bottom row) and were placed consistently across samples. (b) Responses in patient #12 are shown at all 5 time points. Every possible combination of responses is shown on the x axis. Responses are grouped and color coded according to the number of functions. Bars indicate the percentage of the total response contributed by CD8+ T cells with a given functional response. (c) Each pie represents a time point in patient #12 and each slice of the pie represents the fraction of the total response that consists of CD8+ T cells positive for a given number functions.
Similar articles
- MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW, Merrill P, Fink R, Woodson EM, Wiernasz CJ, Patterson JW, Slingluff CL Jr. Chianese-Bullock KA, et al. J Immunol. 2005 Mar 1;174(5):3080-6. doi: 10.4049/jimmunol.174.5.3080. J Immunol. 2005. PMID: 15728523 - Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP. Weber J, et al. Cancer. 2003 Jan 1;97(1):186-200. doi: 10.1002/cncr.11045. Cancer. 2003. PMID: 12491520 Clinical Trial. - Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.
Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA. Slingluff CL Jr, et al. Clin Cancer Res. 2009 Nov 15;15(22):7036-44. doi: 10.1158/1078-0432.CCR-09-1544. Epub 2009 Nov 10. Clin Cancer Res. 2009. PMID: 19903780 Free PMC article. Clinical Trial. - Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.
Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales MA. Chang DZ, et al. Hematology. 2004 Jun;9(3):207-15. doi: 10.1080/10245330410001701549. Hematology. 2004. PMID: 15204102 Review. - Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison.
Quinn C, Ma Q, Kudlac A, Palmer S, Barber B, Zhao Z. Quinn C, et al. Adv Ther. 2017 Feb;34(2):495-512. doi: 10.1007/s12325-016-0464-9. Epub 2016 Dec 20. Adv Ther. 2017. PMID: 28000169 Free PMC article. Review.
Cited by
- The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics.
Muslimov A, Tereshchenko V, Shevyrev D, Rogova A, Lepik K, Reshetnikov V, Ivanov R. Muslimov A, et al. Int J Mol Sci. 2023 Oct 1;24(19):14820. doi: 10.3390/ijms241914820. Int J Mol Sci. 2023. PMID: 37834268 Free PMC article. Review. - Enhanced synergistic antitumor effect of a DNA vaccine with anticancer cytokine, MDA-7/IL-24, and immune checkpoint blockade.
Miri SM, Pourhossein B, Hosseini SY, Keshavarz M, Shahmahmoodi S, Zolfaghari MR, Mohebbi SR, Gorji A, Ghaemi A. Miri SM, et al. Virol J. 2022 Jun 25;19(1):106. doi: 10.1186/s12985-022-01842-x. Virol J. 2022. PMID: 35752792 Free PMC article. - Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement.
Chin AL, Jiang S, Jang E, Niu L, Li L, Jia X, Tong R. Chin AL, et al. Nat Commun. 2021 Aug 26;12(1):5138. doi: 10.1038/s41467-021-25391-z. Nat Commun. 2021. PMID: 34446702 Free PMC article. - Improving human cancer therapy through the evaluation of pet dogs.
LeBlanc AK, Mazcko CN. LeBlanc AK, et al. Nat Rev Cancer. 2020 Dec;20(12):727-742. doi: 10.1038/s41568-020-0297-3. Epub 2020 Sep 15. Nat Rev Cancer. 2020. PMID: 32934365 Review. - Adjuvanted influenza vaccines.
Tregoning JS, Russell RF, Kinnear E. Tregoning JS, et al. Hum Vaccin Immunother. 2018 Mar 4;14(3):550-564. doi: 10.1080/21645515.2017.1415684. Epub 2018 Jan 25. Hum Vaccin Immunother. 2018. PMID: 29232151 Free PMC article. Review.
References
- Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales MA. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology. 2004;9:207–215. - PubMed
- Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:3539–3543. - PMC - PubMed
- Kielian T, Nagai E, Ikubo A, Rasmussen CA, Suzuki T. Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo. Cancer Immunol Immunother. 1999;48:123–131. - PMC - PubMed
- Shinohara H, Yano S, Bucana CD, Fidler IJ. Induction of chemokine secretion and enhancement of contact-dependent macrophage cytotoxicity by engineered expression of granulocyte-macrophage colony-stimulating factor in human colon cancer cells. J Immunol. 2000;164:2728–2737. - PubMed
- Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. Journal of Urology. 1994;151:622–628. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 CA059350/CA/NCI NIH HHS/United States
- CA59350/CA/NCI NIH HHS/United States
- CA33049/CA/NCI NIH HHS/United States
- K08 CA102606/CA/NCI NIH HHS/United States
- P01 CA033049-20/CA/NCI NIH HHS/United States
- K08 CA102606-01/CA/NCI NIH HHS/United States
- P01 CA033049/CA/NCI NIH HHS/United States
- CA10260/CA/NCI NIH HHS/United States
- P01 CA059350-11/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials